Opinion|Videos|December 3, 2024
Understanding PIRA in MS: Key Insights and Advances From ECTRIMS 2024
Author(s)Gabriel Pardo, MD, FAAN, Martin Belkin, DO
Key Takeaways
- PIRA represents MS progression without clinical relapses, impacting patients' quality of life by contributing to disability accumulation.
- Unlike RAW, PIRA reflects insidious progression, often undetected by traditional relapse-focused assessments.
Panelists discuss how progression independent of relapse activity (PIRA) in multiple sclerosis (MS) represents continuous neurological decline unrelated to inflammatory events, distinct from relapse-associated worsening (RAW). Recent ECTRIMS 2024 presentations emphasized standardized evaluation methods to better understand disease progression and improve patient management strategies.
Advertisement
Video content above is prompted by the following:
- Cognition and PIRA in MS have received a lot of attention in recent years.
- Please provide an overview of PIRA and its potential impact on a patient’s quality of life.
- How is PIRA different from RAW?
- How is PIRA evaluated? Discuss presentations from ECTRIMS 2024 by Muller and others about standardization of PIRA evaluation and why it might matter.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Early Results Show Symptom Gains in First Patient Dosed With UX-DA001 Cell Therapy for Parkinson Disease
2
Bringing Biomarkers to the Bedside: The Clinical Promise of Abbott’s TBI Test
3
Understanding Key Clinical and Genetic Biomarkers in Huntington Disease Research: Sarah O'Shea, MD, MSc
4
De-Escalation Strategies in Multiple Sclerosis: Oral Therapies and Cladribine
5
